ReviewCurrent pharmaceutical design2022
Exploring the Phosphatidylcholine in Inflammatory Bowel Disease: Potential Mechanisms and Therapeutic Interventions.
Review in Current pharmaceutical design, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Novel insights intomSystems · 2026Article
- Alterations in secondary lipids are associated with neuroinflammation in the brain of Neu1-deficient mice.Cell and tissue research · 2026Article
- Differential Tear Lipid Metabolomics Signatures Discriminate Superior Limbic Keratoconjunctivitis From Dry Eye Disease.Translational vision science & technology · 2025Article
- Causal Association of Plasma Lipidome With Inflammatory Bowel Diseases and Mediating Role of Circulating Inflammatory Proteins: A Mendelian Randomization Study.Food science & nutrition · 2025Article
- Inhibition of intracellular versus extracellular cathepsin D differentially alters the liver lipidome of mice with metabolic dysfunction-associated steatohepatitis.The FEBS journal · 2025Article
- Exosomes in Precision Oncology and Beyond: From Bench to Bedside in Diagnostics and Therapeutics.Cancers · 2025Review
- Effect of Freeze Drying and Hot Air Drying on the Composition and Bioactivities of Lipids from Razor ClamFoods (Basel, Switzerland) · 2025Article
- Single-cell nanocapsules of gut microbiota facilitate fecal microbiota transplantation.Theranostics · 2025Article
- Plasma lipidomic signatures reveal age-associated patterns of septic shock risk and immune dysregulation in sepsis.Frontiers in immunology · 2025Article
- Article
- The causal relationship and potential mediators between plasma lipids and atopic dermatitis: a bidirectional two-sample, two-step mendelian randomization.Lipids in health and disease · 2024Article
- Unbiased serum metabolomic analysis in cats with naturally occurring chronic enteropathies before and after medical intervention.Scientific reports · 2024Article
- Genotype-based "virtual" metabolomics in a clinical biobank identifies novel metabolite-disease associations.Frontiers in genetics · 2024Article
- Genotype-based "virtual" metabolomics in a clinical biobank identifies novel metabolite-disease associations.Research square · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel disease (IBD) is a significant health problem with an increasing financial burden worldwide. Although various treatment strategies have been used, the results were not satisfactory. More and more researches have proved that the application of phosphatidylcholine (PC) may become an alternative therapy for IBD.
objectiveThis review aims to provide an overview of the possible mechanisms of PC and promote the potential application of PC for IBD therapy further.
methodsA comprehensive literature search was performed in PubMed with the following keywords: 'phosphatidylcholine', 'inflammatory bowel disease', 'Crohn's disease', 'inflammation', 'ulcerative colitis', 'therapy', 'nanomedicines', 'PKCζ', 'lysophosphatidylcholine', 'microbiota' and 'drug carrier'. The logical operators "AND" and "OR" were applied to combine different sets of the search results.
resultsStudies suggested that PC displays a significant effect in the treatment of IBD by modulating gut barrier function, remodeling gut microbiota structure, regulating polarization of macrophages, and reducing the inflammatory response. PC has also been exploited as a drug carrier for anticancer or anti-inflammation agents in multiple forms, which implies that PC has immense potential for IBD therapy.
conclusionPC has shown promising potential as a new therapeutic agent or a drug carrier, with a novel, stable, prolonged mechanism of action in treating IBD. However, more high-quality basic and clinical studies are needed to confirm this.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.